CTLA-4 Expression in Tumor-infiltrating Lymphocytes Is Irrelevant to PD-L1 Expression in NSCLC.
CTLA-4 antigen
Ipilimumab
immune checkpoint inhibitors
non-small cell lung cancer
regulatory T cells
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
04
10
2021
revised:
25
10
2021
accepted:
26
10
2021
entrez:
1
12
2021
pubmed:
2
12
2021
medline:
16
12
2021
Statut:
ppublish
Résumé
Treatments containing ipilimumab have shown a good outcome in patients with non-small cell lung cancer (NSCLC) regardless of the PD-L1 tumor proportion score (TPS). However, the association between PD-L1 TPS and the expression of CTLA-4 in tumor-infiltrating lymphocytes is unknown. Fifty-five NSCLC patients who underwent surgery in our hospital were included in this study. We measured the proportions of CTLA-4 Statistical correlations were found neither between the proportion of CTLA-4 The proportions of CTLA-4
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Treatments containing ipilimumab have shown a good outcome in patients with non-small cell lung cancer (NSCLC) regardless of the PD-L1 tumor proportion score (TPS). However, the association between PD-L1 TPS and the expression of CTLA-4 in tumor-infiltrating lymphocytes is unknown.
PATIENTS AND METHODS
METHODS
Fifty-five NSCLC patients who underwent surgery in our hospital were included in this study. We measured the proportions of CTLA-4
RESULTS
RESULTS
Statistical correlations were found neither between the proportion of CTLA-4
CONCLUSION
CONCLUSIONS
The proportions of CTLA-4
Identifiants
pubmed: 34848482
pii: 41/12/6267
doi: 10.21873/anticanres.15447
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
CTLA-4 Antigen
0
CTLA4 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6267-6272Informations de copyright
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.